10 powodów, dzięki którym terapia astmy i przewlekłej obturacyjnej choroby płuc salmeterolem z propionianem flutykazonu w inhalatorze DPI może być bardzo skuteczna i bezpieczna Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 15, 2023
Słowa kluczowe:
astma, przewlekła obturacyjna choroba płuc, salmaterol, fluktykazon, DPI, inhalator
##plugins.themes.bootstrap3.article.main##
Abstrakt
Długo działające β2-mimetyki i wziewne glikokortykosteroidy są szeroko stosowane w leczeniu astmy i przewlekłej obturacyjnej choroby płuc od wielu lat. W terapii astmy i przewlekłej obturacyjnej choroby płuc dostępna jest szeroka gama długo działających β2-mimetyków i wziewnych glikokortykosteroidów oraz ich połączeń. Od prawie 20 lat stosuje się połączenie salmeterolu z propionianem flutykazonu dostarczane z inhalatora suchego proszku. Charakteryzuje się ono unikalnymi cechami tych składników, w tym wysoką selektywnością i siłą działania, które u chorych na astmę i przewlekłą obturacyjną chorobę płuc wywierają synergistyczny wpływ na czynność płuc i proces zapalny w drogach oddechowych. W osiągnięciu wysokiej skuteczności klinicznej pomaga również bardzo wygodny system podawania, dzięki niewielkiej liczbie błędów popełnianych podczas inhalacji i znacznemu stopniowi akceptacji inhalatora przez pacjentów.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kowal, K. (2023). 10 powodów, dzięki którym terapia astmy i przewlekłej obturacyjnej choroby płuc salmeterolem z propionianem flutykazonu w inhalatorze DPI może być bardzo skuteczna i bezpieczna. Alergoprofil, 19(1), 17-22. https://doi.org/10.24292/01.AP.191150623
Numer
Dział
THERAPY
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Global Initiative for Asthma (GINA) Main Report. 2022 GINA Report, Global Strategy for Asthma Management and Prevention (access: 14.04.2023).
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report. Global Initiative for Chronic Obstructive Lung Disease; 2023 (access: 14.04.2023).
3. Hough KP, Curtiss ML, Blain TJ et al. Airway Remodeling in Asthma. Front Med. 2020; 7: 191.
4. Wang Y, Xu J, Meng Y et al. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018; 13: 3341-8.
5. Kuruvilla ME, Lee FE, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clin Rev Allergy Immunol. 2019; 56: 219-33.
6. Yousuf A, McAuley H, Elneima O et al. The different phenotypes of COPD. Br Med Bull. 2021; 137: 82-97.
7. Liang Y, Mak JCW. Inhaled Therapies for Asthma and Chronic Obstructive Pulmonary Disease. Curr Pharm Des. 2021; 27: 1469-81.
8. Emeryk A, Pirożyński M, Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018; 86: 44-52.
9. Adkins JC, McTavish D. Salmeterol: a review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs. 1997; 54: 331-54.
10. Cazzola M, Rogliani P, Matera MG. Ultra-LABAs for the treatment of asthma. Respir Med. 2019; 156: 47-52.
11. Cates CJ, Jaeschke R, Schmidt S et al. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2013; (3): CD006922.
12. Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015; 80: 372-80.
13. Ringdal N, Swinburn P, Backman R et al. A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation. Mediators Inflamm. 1996; 5: 382-9.
14. Pauwels RA, Yernault JC, Demedts MG et al. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. Am J Respir Crit Care Med. 1998; 157: 827-32.
15. O’Reilly JF, Weir DC, Banham S et al. Is high-dose fluticasone propionate via a metered-dose inhaler and Volumatic as efficacious as nebulized budesonide in adult asthmatics? Respir Med. 1998; 92: 111-7.
16. Pace E, Gagliardo R, Melis M et al. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J Allergy Clin Immunol. 2004; 114: 1216-23.
17. Volonaki E, Psarras S, Xepapadaki P et al. Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus- induced epithelial production of remodelling-associated growth factors. Clin Exp Allergy. 2006; 36: 1268-73.
18. Barnes NC, Qiu YS, Pavord ID et al.; SCO30005 Study Group. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006; 173: 736-43.
19. Nelson HS, Chapman KR, Pyke SD et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003; 112: 29-36.
20. Kirby S, Falcoz C, Daniel MJ et al. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol. 2001; 56: 781-91.
21. Bateman ED, Britton M, Carrillo J et al. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Invest. 1998; 16: 193-201.
22. Chapman KR, Ringdal N, Backer V et al. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Discus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J. 1999; 6: 45-51.
23. Pirozynski M, Sosnowski TR. Inhalation devices: from basic science to practical use, innovative vs generic products. Expert Opin Drug Deliv. 2016; 13: 1559-71.
24. Ramadan WH, Sarkis AT. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study. Chron Respir Dis. 2017; 14: 309-20.
25. Woodcock A, Janson C, Rees J et al. Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax. 2022; 77: 1187-92.
26. Al-Showair RA, Tarsin WY, Assi KH et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007; 101: 2395-401.
27. Fuller R. The Diskus: a new multi-dose powder device-efficacy and comparison with Turbuhaler. J Aerosol Med. 1995; 8 Suppl 2: S11-7.
28. Grabowski M, Barg W, Chmielowicz B et al. The variability of peak inspiratory flow (PIF) on valves imitating dry powder inhalers resistance during asthma and COPD exacerbations. Pneumonol Alergol Pol. 2007; 75: 324-30.
29. Kamps AW, Brand PL, Roorda RJ. Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr Pulmonol. 2004; 37: 65-70.
30. Chrystyn H. The Diskus: a review of its position among dry powder inhaler devices. Int J Clin Pract. 2007; 61: 1022-36.
31. Khassawneh BY, Al-Ali MK, Alzoubi KH et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care. 2008; 53: 324-8.
32. Rootmensen GN, van Keimpema AR, Jansen HM et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv. 2010; 23: 323-8.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report. Global Initiative for Chronic Obstructive Lung Disease; 2023 (access: 14.04.2023).
3. Hough KP, Curtiss ML, Blain TJ et al. Airway Remodeling in Asthma. Front Med. 2020; 7: 191.
4. Wang Y, Xu J, Meng Y et al. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018; 13: 3341-8.
5. Kuruvilla ME, Lee FE, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clin Rev Allergy Immunol. 2019; 56: 219-33.
6. Yousuf A, McAuley H, Elneima O et al. The different phenotypes of COPD. Br Med Bull. 2021; 137: 82-97.
7. Liang Y, Mak JCW. Inhaled Therapies for Asthma and Chronic Obstructive Pulmonary Disease. Curr Pharm Des. 2021; 27: 1469-81.
8. Emeryk A, Pirożyński M, Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018; 86: 44-52.
9. Adkins JC, McTavish D. Salmeterol: a review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs. 1997; 54: 331-54.
10. Cazzola M, Rogliani P, Matera MG. Ultra-LABAs for the treatment of asthma. Respir Med. 2019; 156: 47-52.
11. Cates CJ, Jaeschke R, Schmidt S et al. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2013; (3): CD006922.
12. Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015; 80: 372-80.
13. Ringdal N, Swinburn P, Backman R et al. A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation. Mediators Inflamm. 1996; 5: 382-9.
14. Pauwels RA, Yernault JC, Demedts MG et al. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. Am J Respir Crit Care Med. 1998; 157: 827-32.
15. O’Reilly JF, Weir DC, Banham S et al. Is high-dose fluticasone propionate via a metered-dose inhaler and Volumatic as efficacious as nebulized budesonide in adult asthmatics? Respir Med. 1998; 92: 111-7.
16. Pace E, Gagliardo R, Melis M et al. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J Allergy Clin Immunol. 2004; 114: 1216-23.
17. Volonaki E, Psarras S, Xepapadaki P et al. Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus- induced epithelial production of remodelling-associated growth factors. Clin Exp Allergy. 2006; 36: 1268-73.
18. Barnes NC, Qiu YS, Pavord ID et al.; SCO30005 Study Group. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006; 173: 736-43.
19. Nelson HS, Chapman KR, Pyke SD et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003; 112: 29-36.
20. Kirby S, Falcoz C, Daniel MJ et al. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol. 2001; 56: 781-91.
21. Bateman ED, Britton M, Carrillo J et al. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Invest. 1998; 16: 193-201.
22. Chapman KR, Ringdal N, Backer V et al. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Discus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J. 1999; 6: 45-51.
23. Pirozynski M, Sosnowski TR. Inhalation devices: from basic science to practical use, innovative vs generic products. Expert Opin Drug Deliv. 2016; 13: 1559-71.
24. Ramadan WH, Sarkis AT. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study. Chron Respir Dis. 2017; 14: 309-20.
25. Woodcock A, Janson C, Rees J et al. Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax. 2022; 77: 1187-92.
26. Al-Showair RA, Tarsin WY, Assi KH et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007; 101: 2395-401.
27. Fuller R. The Diskus: a new multi-dose powder device-efficacy and comparison with Turbuhaler. J Aerosol Med. 1995; 8 Suppl 2: S11-7.
28. Grabowski M, Barg W, Chmielowicz B et al. The variability of peak inspiratory flow (PIF) on valves imitating dry powder inhalers resistance during asthma and COPD exacerbations. Pneumonol Alergol Pol. 2007; 75: 324-30.
29. Kamps AW, Brand PL, Roorda RJ. Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr Pulmonol. 2004; 37: 65-70.
30. Chrystyn H. The Diskus: a review of its position among dry powder inhaler devices. Int J Clin Pract. 2007; 61: 1022-36.
31. Khassawneh BY, Al-Ali MK, Alzoubi KH et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care. 2008; 53: 324-8.
32. Rootmensen GN, van Keimpema AR, Jansen HM et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv. 2010; 23: 323-8.